Oncotarget

Research Papers:

Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients

Gladys Morrison, Divya Lenkala, Bonnie LaCroix, Dana Ziliak, Vandana Abramson, Phuong Khanh Morrow, Andres Forero, Catherine Van Poznak, Hope S Rugo, Rita Nanda, Peter H. O’Donnell, R. Stephanie Huang _

PDF |  HTML  |  Supplementary Files  |  Author Information  |  Order a Reprint

Oncotarget. 2016; 7:38359-38366. doi: 10.18632/oncotarget.9521

Metrics: PDF 397 views  |   HTML 167 views  |   ?  


Abstract

Gladys Morrison1,2, Divya Lenkala1, Bonnie LaCroix1, Dana Ziliak1, Vandana Abramson3, Phuong Khanh Morrow4, Andres Forero5, Catherine Van Poznak6, Hope S Rugo7, Rita Nanda1, Peter H. O’Donnell1,2, R. Stephanie Huang1,2

1Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA

2Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL, USA

3Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

4Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

5Department of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

6Department of Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

7University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Correspondence to:

R. Stephanie Huang, email: rhuang@medicine.bsd.uchicago.edu

Keywords: breast cancer, lymphoblastoid cell lines, patient-derived model, capecitabine, ex vivo model

Received: March 17, 2016     Accepted: April 27, 2016     Published: May 20, 2016

ABSTRACT

Capecitabine is commonly used in treating breast cancer; however, therapeutic response varies among patients and there is no clinically validated model to predict individual outcomes. Here, we investigated whether drug sensitivity quantified in ex vivo patients’ blood-derived cell lines can predict response to capecitabine in vivo. Lymphoblastoid cell lines (LCLs) were established from a cohort of metastatic breast cancer patients (n = 53) who were prospectively monitored during treatment with single agent capecitabine at 2000 mg/m2/day. LCLs were treated with increasing concentrations of 5’-DFUR, a major capecitabine metabolite, to assess patients’ ex vivo sensitivity to this drug. Subsequently, ex vivo phenotype was compared to observed patient disease response and drug induced-toxicities. We acquired an independent cohort of breast cancer cell lines and LCLs derived from the same donors from ATCC, compared their sensitivity to 5’-DFUR. As seen in the patient population, we observed large inter-individual variability in response to 5’-DFUR treatment in patient-derived LCLs. Patients whose LCLs were more sensitive to 5’-DFUR had a significantly longer median progression free survival (9-month vs 6-month, log rank p-value = 0.017). In addition, this significant positive correlation for 5’-DFUR sensitivity was replicated in an independent cohort of 8 breast cancer cell lines and LCLs derived from the same donor. Our data suggests that at least a portion of the individual sensitivity to capecitabine is shared between germline tissue and tumor tissue. It also supports the utility of patient-derived LCLs as a predictive model for capecitabine treatment efficacy in breast cancer patients.

Author Information

Gladys Morrison

Divya Lenkala

Bonnie LaCroix

Dana Ziliak

Vandana Abramson

Phuong Khanh Morrow

Andres Forero

Catherine Van Poznak

Hope S Rugo

Rita Nanda

Peter H. O’Donnell

R. Stephanie Huang
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9521